Bo Kruse Sells 4,000 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CFO Bo Kruse sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, November 22nd. The shares were sold at an average price of $18.09, for a total transaction of $72,360.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Bo Kruse also recently made the following trade(s):

  • On Friday, October 22nd, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $25.94, for a total transaction of $103,760.00.
  • On Monday, October 4th, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $28.78, for a total transaction of $115,120.00.
  • On Wednesday, September 22nd, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $30.82, for a total transaction of $123,280.00.
  • On Tuesday, September 7th, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $32.03, for a total transaction of $128,120.00.

NASDAQ YMAB opened at $17.73 on Thursday. Y-mAbs Therapeutics, Inc. has a 12-month low of $16.40 and a 12-month high of $55.00. The firm has a market capitalization of $773.81 million, a P/E ratio of -19.06 and a beta of 1.08. The firm has a 50 day simple moving average of $26.73.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Thursday, November 4th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 83.21% and a negative return on equity of 19.08%. The firm had revenue of $8.97 million during the quarter, compared to the consensus estimate of $10.87 million. During the same period in the prior year, the business posted ($0.82) earnings per share. Analysts anticipate that Y-mAbs Therapeutics, Inc. will post -1.12 EPS for the current year.

Several equities analysts recently commented on YMAB shares. HC Wainwright reiterated a “buy” rating and set a $68.00 target price on shares of Y-mAbs Therapeutics in a research note on Friday, October 8th. JPMorgan Chase & Co. cut shares of Y-mAbs Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $57.00 to $30.00 in a research note on Tuesday, November 16th. Morgan Stanley began coverage on shares of Y-mAbs Therapeutics in a research note on Friday, November 19th. They issued an “equal weight” rating and a $25.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 10th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of “Buy” and a consensus price target of $49.00.

Institutional investors have recently made changes to their positions in the company. Point72 Hong Kong Ltd bought a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at about $28,000. HighMark Wealth Management LLC raised its stake in Y-mAbs Therapeutics by 265.0% in the second quarter. HighMark Wealth Management LLC now owns 1,281 shares of the company’s stock valued at $43,000 after purchasing an additional 930 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Y-mAbs Therapeutics in the third quarter valued at about $49,000. BNP Paribas Arbitrage SA raised its stake in Y-mAbs Therapeutics by 322.1% in the third quarter. BNP Paribas Arbitrage SA now owns 6,449 shares of the company’s stock valued at $184,000 after purchasing an additional 4,921 shares in the last quarter. Finally, Amalgamated Bank acquired a new position in Y-mAbs Therapeutics in the second quarter valued at about $223,000. 59.92% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

See Also: Google Finance

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.